Spyryx Biosciences (United States)

Recent papers from Spyryx Biosciences (United States)

1. SPX-101 is stable in and retains function after exposure to cystic fibrosis sputumJournal of Cystic Fibrosis · 2018
2. Cigarette smoke modifies and inactivates SPLUNC1, leading to airway dehydrationThe FASEB Journal · 2018
3. Evaluation of a SPLUNC1-derived peptide for the treatment of cystic fibrosis lung diseaseAJP Lung Cellular and Molecular Physiology · 2017
4. Nonclinical safety assessment of SPX-101, a novel peptide promoter of epithelial sodium channel internalization for the treatment of cystic fibrosisInhalation Toxicology · 2017
5. SPX-101 Is a Novel Epithelial Sodium Channel–targeted Therapeutic for Cystic Fibrosis That Restores Mucus TransportAmerican Journal of Respiratory and Critical Care Medicine · 2017
6. Combined targeting of SET and tyrosine kinases provides an effective therapeutic approach in human T-cell acute lymphoblastic leukemiaOncotarget · 2016
7. Inhaled protein/peptide-based therapies for respiratory diseaseMolecular and Cellular Pediatrics · 2016